Episode
Reversing Parkinson’s in Mice, Protecting Primates from HIV, Top 10 Biotech Clusters, and Sarepta
- Podcast
- Touching Base
- Published
- Aug 8, 2025
- Duration seconds
- 2062
- Processing state
not_requested- Canonical source
- https://shows.acast.com/touching-base/episodes/reversing-parkinsons-in-mice-protecting-primates-from-hiv-to
Actions
POST https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/reversing-parkinson-s-in-mice-protecting-primates-from-hiv-top-10-biotech-clusters-and-sarepta/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/touching-base-6714887/reversing-parkinson-s-in-mice-protecting-primates-from-hiv-top-10-biotech-clusters-and-sarepta.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This episode of GEN 's Touching Base spotlights the unexpected relationship between breathing low oxygen and restoration of neuron function in a mouse model of Parkinson’s disease. In addition, a single gene therapy injected at birth now offers lasting protection from HIV in infant rhesus macaques. Rounding out our episode, we discuss key factors shaping this year’s A-List of Top 10 U.S. Biopharma Clusters and recap the regulatory conflict surrounding Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy, Elevidys®—including the departure of Vinay Prasad, MD, the FDA official behind the agency’s brief get-tough approach. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : GLP-1 Drug Semaglutide Linked to Reduced Muscle Strength in Mice GEN, August 6, 2025 Out of Thin Air: Hypoxia Reverses Parkinson’s Symptoms in Mice By Fay Lin, PhD GEN, August 6, 2025 Early Gene Therapy Provides Lasting HIV Protection in Newborn Primates GEN, July 30, 2025 StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks By Alex Philippidis, GEN Edge, August 3, 2025 Sarepta to Resume Shipping DMD Gene Therapy to Ambulant Patients By Alex Philippidis, GEN Edge, July 28, 2025 Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs By Alex Philippidis, Uduak Thomas, Fay Lin, PhD, Corinna Singleman, PhD, GEN, July 25, 2025 About Face: Sarepta to Pause Elevidys Shipments Temporarily By Alex Philippidis, GEN Edge, July 21, 2025 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State o…